Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated recurrent ovarian cancer.

被引：2
|
作者：
Sanchez-Munoz, A.
Mendiola, C.
Rodriguez, C. A.
Perez-Ruiz, E.
Jurado, J. M.
Alonso-Carrion, L.
Ghanem, I.
Deelasco, G.
Quero Blanco, C.
Alba, E.
机构：
[1] Hosp Univ Virgen de la Victoria, Med Oncol Serv, Malaga, Spain
[2] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
[3] Hosp Univ Salamanca, Dept Oncol, Salamanca, Spain
[4] Hosp Univ Virgen de la Victoria, Malaga, Spain
[5] Hosp Univ Clin San Cecilio, Granada, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e15507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15507
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
    Sanchez-Munoz, Alfonso
    Mendiola, Cesar
    Perez-Ruiz, Elisabeth
    Rodriguez-Sanchez, Cesar A.
    Miguel Jurado, Jose
    Alonso-Carrion, Lorenzo
    Ghanem, Ismael
    de Velasco, Guillermo
    Quero-Blanco, Cristina
    Alba, Emilio
    [J]. ONCOLOGY, 2010, 79 (1-2) : 98 - 104
  • [2] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [3] BEVACIZUMAB PLUS METRONOMIC CYCLOPHOSPHAMIDE FOR HEAVILY PRETREATED OVARIAN CANCER: A SINGLE INSTITUTION EXPERIENCE
    Ghanem, I.
    Mendiola, C.
    Diaz, A.
    Velasco, G.
    Manso, L.
    Ciruelos, E.
    Manneh, R. A.
    Hoyos, S.
    Pascual, T.
    Cortes-Funes, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 325 - 325
  • [4] Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
    Isono-Nakata, Rose
    Tsubamoto, Hiroshi
    Ueda, Tomoko
    Inoue, Kayo
    Shibahara, Hiroaki
    [J]. GYNECOLOGIC ONCOLOGY REPORTS, 2018, 24 : 57 - 60
  • [5] CLINICAL BENEFIT OF ORAL METRONOMIC CYCLOPHOSPHAMIDE ADMINISTRATION IN HEAVILY PRETREATED RECURRENT EPITHELIAL OVARIAN CANCER
    Attianese, D.
    Badellino, E.
    Villa, M.
    Bellero, M.
    Massobrio, R.
    Fuso, L.
    Biglia, N.
    Ferrero, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A230 - A230
  • [6] Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
    Jain, Salvia Sanjay
    Makeyev, Yan G.
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Fishman, David
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] The combination of intravenous bevacizumab and metronomic oral cyclophosphamide for recurrent platinum-resistant ovarian cancer.
    Barber, Emma L.
    Neubauer, Nikki Lynn
    Zsiros, Emese
    Schink, Julian C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer
    Scheusan, R.
    Curescu, S.
    Stanculeanu, D.
    Curescu, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] BEVACIZUMAB WITH METRONOMIC ORAL CYCLOPHOSPHAMIDE FOR PATIENTS WITH RECURRENT CERVICAL CANCER
    Isono, R.
    Goto, M.
    Takimoto, Y.
    Ueda, T.
    Inoue, K.
    Ito, K.
    Tsubamoto, H.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A145 - A146
  • [10] Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment
    Aigner, Julia
    Bischofs, Esther
    Hallscheidt, Peter
    Sohn, Christof
    Schneeweiss, Andreas
    Eichbaum, Michael
    [J]. ANTI-CANCER DRUGS, 2011, 22 (10) : 1030 - 1033
12345